Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adaptive Biotechnologies Corporation - Common Stock
(NQ:
ADPT
)
16.24
-0.18 (-1.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Adaptive Biotechnologies Corporation - Common Stock
< Previous
1
2
3
Next >
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
December 15, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
December 09, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
December 06, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
November 24, 2025
Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug development
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
November 06, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
October 15, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 27, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
August 05, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
July 15, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
July 01, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
May 30, 2025
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
May 01, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
April 10, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
April 08, 2025
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
March 11, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
February 05, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
January 22, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
January 14, 2025
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
January 07, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
December 07, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
December 03, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
November 07, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
October 09, 2024
From
Adaptive Biotechnologies
Via
GlobeNewswire
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
August 29, 2024
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies
From
Adaptive Biotechnologies
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
